Bringing Precision Medicine to Brain Tumors

Therillume is a clinical-stage neuro-oncology therapeutics company bringing precision medicine to patients with Glioblastoma (GBM) and Neurofibromatosis Types 1 and 2 (NF1 and NF2). Therillume is a human therapeutic company, spinning out from Recombinetics Inc., and leveraging its pioneering precise gene-editing platform and intellectual property to identify, validate and expedite high-quality candidates through clinical development.

Check out our latest publication showing the power of combination therapy for treating Neurofibromatosis Type 1:

Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1: Molecular Therapy - Nucleic Acids 

https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(23)00166-X

 FACING THE FACTS

Glioblastoma (GBM)

 Neurofibromatosis Type 1 (NF1)

Seeking investment and strategic partnerships

Reach out today for information on how you can make a difference